Current Studies
The Office of Clinical Trials is currently recruiting for the following studies:
CARDIAC STUDIES
PRECISION (Wilson Medical Center only) – this study compares cardiovascular
safety of Celebrex vs. Naprosyn and Ibuprofen in osteoarthritis or rheumatoid
arthritis patients with or at high risk for cardiovascular disease. Sponsor: Pfizer Principal Investigator: Dr. Hisham Kashou
ROCHE (Wilson Medical Center only) – this study evaluates the effects of study
medication on cardiovascular risk in stable heart disease patients with
documented recent ACS. Sponsor: Roche Principal Investigator: Dr. Hisham Kashou
TRILOGY - TABY (Wilson Medical Center only) – this study compares two
medications in ACS patients with unstable angina/non-ST elevation MI who are
medically managed Sponsor: Eli Lilly Principal Investigator: Dr. Hisham Kashou
TRIDENT 1 (Biogen) - this study will evaluate a new medication in the treatment
of patients with exacerbation of chronic congestive heart failure and renal
insufficiency on total fluid loss after treatment Sponsor: Biogen Idec Principal Investigator: Dr. Hisham Kashou
BOREALIS - this study evaluates the effectiveness of a new medication given as a
once weekly injection versus Warfarin in reducing embolic events in patients
with atrial fibrillation Sponsor: Sanofi-Aventis Principal Investigator: Dr. Hisham Kashou
RED CABG (Wilson Medical Center only) – this study evaluates the effect of Acadesine on clinically significan adverse cardiovascular and cerebrovascular
events in high risk patients undergoing coronary artery bypass graft surgery
using cardiopulmonary bypass Sponsor: Schering Plough Principal Investigator: Dr. M. Bashar Yousuf
SURGICAL STUDIES
IPET (Wilson Medical Center only) – this study evaluates the effectiveness on
the INTACT system in obtaining the entire specimen in patient undergoing breast
biopsy Sponsor: Intact Medical Principal Investigator: Dr. Michael Farrell
ZYMOGENETICS REEXPOSURE (Wilson Medical Center only) – this study evaluates the
immunogenicity and safety of topical recombinant thrombin (rThrombin) in
surgical hemostasis in patients previously exposed to rThrombin Sponsor: Zymogenetics
Principal Investigators: Dr. Khalid Sethi
NEUROLOGICAL STUDIES
MITSUBISHI (Wilson Memorial Regional Medical Center only) – this study evaluates
the effectiveness of a new medication on patient experiencing acute stroke
symptoms within a 3-6 hour window of symptom onset Sponsor: Mitsubishi Principal Investigator: Dr. Aamir Rasheed
PNEUMONIA STUDIES
BAYER/INHALED AMIKACIN - this study evaluates the safety and efficacy of amikacin as adjunctive therapy in intubated and mechanically ventilated patients
with gram negative pneumonia.. Sponsor: Bayer Healthcare Principal Investigator: Dr. Michael Chisdak
BLEEDING STUDIES
BERIPLEX 3003 - this study evaluates the safety and efficacy of a new medication
compared with plasma for rapid reversal of coagulopathy induced by coumadin in
subjects requiring emergency surgery or invasive intervention.. Sponsor: CSL Behring Principal Investigator: Dr. Khalid Sethi
BERIPLEX 3002 - this study evaluates the safety and efficacy of a new medication
compared with plasma for rapid reversal of coagulopathy induced by coumadin in
subjects with acute major bleeding.. Sponsor: CSL Behring Principal Investigator: Dr. Stephen Gomez
